查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493355

美国流式细胞技术市场规模、份额、趋势分析报告：2024-2030 年按产品、技术、应用、最终用途、地区和细分市场进行的预测

U.S. Flow Cytometry Market Size, Share & Trends Analysis Report By Product (Software, Accessories), By Technology (Cell-based, Bead-based), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10个工作天内

价格

美国流式细胞技术市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，美国流式细胞技术市场规模将达到26.1亿美元，2024年至2030年复合年增长率为6.8%。

由于癌症患者和其他慢性病患者的增加，流式细胞技术市场在美国正在迅速扩大。根据美国癌症协会（ACS）统计，2019年美国15岁至39岁的青少年和年轻人约有9,270人因癌症死亡，2020年新增癌症病例约89,500人。预计这些因素将推动市场成长。

COVID-19 大流行对市场产生了积极影响。例如，2020 年 8 月发表在 Springer 上的一项研究发现，週边血单核细胞 (PBMC) 表型的流式细胞技术分析呈现抗原和更有效的适应性免疫反应与 COVID-19 的康復有关。由 COVID-19 爆发导致的感染疾病和慢性病的发病率不断增加，增加了对研究和诊断技术的需求，从而支持了市场的成长。

此外，美国拥有强大的医疗基础设施、大量的医疗支出以及先进的流式细胞技术技术的广泛使用。此外，随着研究型大学从事广泛的研究活动和製药公司的发展，对用于研究目的的流式细胞技术工作流程的需求非常大。这得归功于美国在医疗保健方面的大量投资、高度发展的医疗基础设施以及尖端流式细胞技术技术的广泛使用。

美国流式细胞技术市场报告亮点

  • 以产品来看，设备占据市场主导地位，2023年占35.08%。流式细胞技术仪设备在临床诊断应用中至关重要，例如监测爱滋病毒/爱滋病的进展、检测白血病的微量残存疾病以及评估免疫细胞功能，这将推动该领域的发展。
  • 就技术而言，2023 年的市场占有率将由基于电池的细分市场主导。该技术根据细胞的大小、复杂性和特定分子的存在等特征来分析细胞。同时，以微珠为基础的细分市场预计在预测期内将以最快的复合年增长率成长。
  • 从应用来看，2023年临床细分市场占据最大市场占有率。预计工业领域在预测期内将出现最快的成长。
  • 以最终用途划分，学术机构细分市场在 2023 年占据最大市场占有率。临床测试实验室预计在预测期内成长最快。
  • 美国癌症和爱滋病毒等疾病的发生率急剧上升，推动了对美国流式细胞技术市场的需求。
  • 2024年1月，SONY生物技术发布了高度通用的流式细胞技术分析仪EC800。这种创新设备相容于多种应用，包括粒径测定、免疫表型分析、细胞活力、绝对细胞计数和细胞凋亡检测。 EC800 为各种研究和诊断需求提供了经济高效的解决方案。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国流式细胞技术市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国流式细胞技术市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国流式细胞技术市场：产品估算与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 按产品分類的美国流式细胞技术市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 装置
  • 试剂/耗材
  • 软体
  • 配件
  • 服务

第五章美国流式细胞技术市场：技术评估与趋势分析

  • 2023年及2030年技术市场占有率
  • 细分仪表板
  • 按技术前景分類的美国流式细胞技术市场
  • 2018-2030年市场规模、预测及趋势分析
  • 细胞基础
  • 以微珠为基础

第六章美国流式细胞技术市场：应用预估及趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 美国流式细胞技术市场：按应用分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 研究
  • 产业
  • 临床

第七章美国流式细胞技术市场：最终用途估计和趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 按最终用途分類的美国流式细胞技术市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 临床检测实验室
  • 学术机构
  • 商业组织
  • 医院

第八章美国流式细胞技术市场：区域估计和趋势分析

  • 2023 年和 2030 年按地区分類的市场占有率份额
  • 美国流式细胞技术市场按地区展望
  • 2018-2030年市场规模、预测及趋势分析
  • 西
  • 中西部
  • 东北
  • 西南
  • 东南

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Sysmex Corp
    • Becton, Dickinson, and Company（BD）
    • Danaher Corp
    • Thermo Fisher Scientific, Inc.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • Sony Biotechnology, Inc.
    • Beckman Coulter, Inc.
    • Cytek Biosciences
    • BioLegend, Inc.
    • Enzo Biochem Inc.
    • Cell Signaling Technology, Inc.
    • NeoGenomics Laboratories
    • Q2 Solutions（IQVIA）
    • Elabscience Biotechnology Inc.
    • Stratedigm, Inc.
    • BioLegend, Inc.
    • Union Biometrica, Inc.
    • BennuBio Inc.
    • ORLFO Technologies
Product Code: GVR-4-68040-286-6

U.S. Flow Cytometry Market Growth & Trends:

The U.S. flow cytometry market size is anticipated to reach USD 2.61 billion by 2030 and is growing at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for flow cytometry is expanding faster in the U.S. owing to increased cancer cases and other chronic illnesses. According to the American Cancer Society (ACS), there were roughly 9,270 cancer deaths among adolescents and young adults in the U.S. in 2019 who were between the ages of 15 and 39, and there were about 89,500 new cases of cancer diagnosed in 2020. These factors would drive market growth.

The COVID-19 pandemic had a positive effect on the market. For instance, in August 2020, research published in Springer discovered that flow cytometry analysis of peripheral blood mononuclear cell (PBMC) phenotype helped to predict the risk of COVID-19 clinical progression and indicated that improved antigen presentation and more effective adaptive immune responses are associated with recovery from COVID-19. The increasing frequency of infectious and chronic disorders, most notably the COVID-19 outbreak, has increased the need for technology for study and diagnosis, supporting the market's growth.

Furthermore, the U.S. has a robust healthcare infrastructure, significant healthcare spending, and widespread usage of highly advanced flow cytometry technologies. In addition, owing to research universities engaging in a wide range of research activities and having developed pharmaceutical enterprises, there is an enormous need for flow cytometry workflow for research purposes. This results from the U.S.'s substantial investment in healthcare, highly developed healthcare infrastructure, and widespread usage of cutting-edge flow cytometry technology.

U.S. Flow Cytometry Market Report Highlights:

  • Based on product, instrument dominated the market and accounted for 35.08% in 2023. Flow cytometry instruments are crucial in clinical diagnostics for applications such as immunophenotyping cells to monitor HIV/AIDS progression, detect minimal residual disease in leukemia, and assess immune cell function, which will fuel the segment growth
  • In terms of technology, the cell-based segment dominated the market share in 2023. This technology involves analyzing cells based on their characteristics, such as size, complexity, and the presence of specific molecules. On the other hand, the bead-based segment is expected to grow at the fastest CAGR over the forecast period
  • Based on application, the clinical segment held the largest market share in 2023. The industrial segment is expected to grow fastest over the forecast period
  • In terms of end-use, the academic institute segment held the largest market share in 2023. Clinical testing labsare anticipated to witness the fastest growth over the forecast period
  • The U.S. is the major dominating country in the market due to the surging incidence rate of diseases such as cancer and HIV amongst the population in this country, which is boosting the demand for U.S. flow cytometry market
  • In January 2024, Sony Biotechnology launched the EC800, a highly versatile flow cytometry analyzer. This innovative device caters to various applications, such as particle sizing, immunophenotyping, cell viability, absolute cell counting, and apoptosis detection, among others. The EC800 offers cost-effective solutions suitable for diverse research and diagnostic needs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Region
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Technology Outlook
    • 2.2.3. Application Outlook
    • 2.2.4. End-use Outlook
    • 2.2.5. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Flow Cytometry Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Flow Cytometry Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Flow Cytometry Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Flow Cytometry Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Instruments
      • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2. Cell Analyzers
      • 4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3. Cell Sorters
      • 4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Reagents & Consumables
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Software
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4. Accessories
      • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.5. Services
      • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. U.S. Flow Cytometry Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Flow Cytometry Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Cell-based
      • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Bead-based
      • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. U.S. Flow Cytometry Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Flow Cytometry Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Research
      • 6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
      • 6.4.1.2. Pharmaceutical
      • 6.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.2.2. Drug Discovery
      • 6.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.2.3. In Vitro Toxicity
      • 6.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.2.4. Stem Cell
      • 6.4.1.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.3. Apoptosis
      • 6.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.4. Cell Sorting
      • 6.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.5. Cell Cycle Analysis
      • 6.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.6. Immunology
      • 6.4.1.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.7. Cell Viability
      • 6.4.1.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Industrial
      • 6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Clinical
      • 6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.2. Cancer
      • 6.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.3. Organ Transplantation
      • 6.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.4. Immunodeficiency
      • 6.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.5. Hematology
      • 6.4.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.6. Autoimmune Disorders
      • 6.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Flow Cytometry Market: End-use Estimates & Trend Analysis

  • 7.1. End-use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Flow Cytometry Market by End-use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.4.1. Clinical Testing Labs
      • 7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Academic Institutes
      • 7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Commercial Organizations
      • 7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 7.4.3.2. Biotechnology Companies
      • 7.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 7.4.3.3. Pharmaceutical Companies
      • 7.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 7.4.3.4. CROs
      • 7.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Hospitals
      • 7.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. U.S. Flow Cytometry Market: Region Estimates & Trend Analysis

  • 8.1. Regional Market Share, 2023 & 2030
  • 8.2. U.S. Flow Cytometry Market by Regional Outlook
  • 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 8.3.1. West
      • 8.3.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
    • 8.3.2. Midwest
      • 8.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.3. Northeast
      • 8.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.4. Southwest
      • 8.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.5. Southeast
      • 8.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company heat map analysis, 2023
  • 9.4. Company Profiles
    • 9.4.1. Sysmex Corp
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Becton, Dickinson, and Company (B.D.)
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Danaher Corp
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Thermo Fisher Scientific, Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Agilent Technologies, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Bio-Rad Laboratories, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Sony Biotechnology, Inc.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Beckman Coulter, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Cytek Biosciences
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. BioLegend, Inc.
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Enzo Biochem Inc.
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Cell Signaling Technology, Inc.
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. NeoGenomics Laboratories
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. Q2 Solutions (IQVIA)
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Elabscience Biotechnology Inc.
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. Stratedigm, Inc.
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives
    • 9.4.17. BioLegend, Inc.
      • 9.4.17.1. Company overview
      • 9.4.17.2. Financial performance
      • 9.4.17.3. Product benchmarking
      • 9.4.17.4. Strategic initiatives
    • 9.4.18. Union Biometrica, Inc.
      • 9.4.18.1. Company overview
      • 9.4.18.2. Financial performance
      • 9.4.18.3. Product benchmarking
      • 9.4.18.4. Strategic initiatives
    • 9.4.19. BennuBio Inc.
      • 9.4.19.1. Company overview
      • 9.4.19.2. Financial performance
      • 9.4.19.3. Product benchmarking
      • 9.4.19.4. Strategic initiatives
    • 9.4.20. ORLFO Technologies
      • 9.4.20.1. Company overview
      • 9.4.20.2. Financial performance
      • 9.4.20.3. Product benchmarking
      • 9.4.20.4. Strategic initiativesw

List of Tables

  • Table 1 List of abbreviations
  • Table 2 List of secondary sources
  • Table 3 U.S. flow cytometry market by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. flow cytometry market by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S. flow cytometry market by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. flow cytometry market by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. flow cytometry market by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. flow cytometry market: market outlook
  • Fig. 9 U.S. flow cytometry competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. flow cytometry market driver impact
  • Fig. 15 U.S. flow cytometry market restraint impact
  • Fig. 16 U.S. flow cytometry market strategic initiatives analysis
  • Fig. 17 U.S. flow cytometry market: Product movement analysis
  • Fig. 18 U.S. flow cytometry market: Product outlook and key takeaways
  • Fig. 19 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cell analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Cell sorters market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents & consumables estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Software market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Accessories estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. flow cytometry market: Technology movement analysis
  • Fig. 27 U.S. flow cytometry market: Technology outlook and key takeaways
  • Fig. 28 Cell-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Bead-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. flow cytometry market: Application movement analysis
  • Fig. 31 U.S. flow cytometry market: Application outlook and key takeaways
  • Fig. 32 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 In vitro toxicity market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Stem cell market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Apoptosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Cell sorting market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Cell cycle analysis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Cell viability market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Industrial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Organ transplantation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Immunodeficiency market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Hematology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Autoimmune disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. flow cytometry market: End-use movement analysis
  • Fig. 50 U.S. flow cytometry market: End-use outlook and key takeaways
  • Fig. 51 Clinical testing labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Commercial organizations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 U.S. flow cytometry market: Regional movement analysis
  • Fig. 59 U.S. flow cytometry market: Regional outlook and key takeaways
  • Fig. 60 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)